Fexofenadine PCD Pharma Franchise Company
Cafoli Lifecare offers a comprehensive Fexofenadine PCD pharma franchise built on 14 formulations across tablets and suspension, all manufactured at WHO-GMP certified facilities. This depth gives franchise partners a high-volume antihistamine line for physicians, ENT specialists and paediatricians.
What is Fexofenadine?
Fexofenadine is a third-generation, non-sedating H1-antihistamine and the active metabolite of terfenadine. It selectively blocks peripheral histamine receptors to relieve allergy symptoms without crossing the blood-brain barrier significantly, so it causes minimal drowsiness. Read its profile on MedlinePlus.
Therapeutic Applications
Fexofenadine is prescribed for seasonal and perennial allergic rhinitis and chronic idiopathic urticaria, and is available combined with montelukast for allergic airway disease. Its tablet and paediatric suspension forms suit adults and children. Prescribers include general physicians, ENT surgeons, dermatologists and paediatricians.
Why Fexofenadine is a High-Potential Molecule for Distributors
Fexofenadine is one of the most trusted non-sedating antihistamines and enjoys very high prescription volumes because allergic rhinitis and urticaria are common and recurrent. Its strong non-drowsy reputation supports brand loyalty, and montelukast combinations extend it into respiratory-allergy prescribing. With 14 formulations, a distributor can meet every strength, combination and paediatric need from one fast-moving molecule.
Why Choose Cafoli Lifecare
Cafoli Lifecare provides territory-wise monopoly rights, WHO-GMP certified manufacturing, DCGI-approved formulations, complete promotional inputs and the backing of 1000+ franchise partners across India.
References
- MedlinePlus: Fexofenadine
- PubChem: Fexofenadine
Our formulations of Fexofenadine find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: